29 May 2024
EMA/217318/2024
Human Medicines Division

Overview of (invented) names reviewed in April 2024 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 27-30 May 2024

	NRG meeting 13-14 Feb 2024		NRG meeting 16 April 2024		NRG meeting 18-19 June 2024		NRG meeting 24-25 September 2024		NRG meeting 19-20 November 2024		2024 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names*	69	35	43	38							**112**	**73**
Justification for retention of (invented) name **	8	4	0	1							**8**	**5**

*Includes invented names, INN+MAH/TM and re-use applications.
**In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

	NRG meeting 13-14 Feb 2024		NRG meeting 16 April 2024		NRG meeting 18-19 June 2024		NRG meeting 24-25 September 2024		NRG meeting 19-20 November 2024		2024 total	
	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed
Total number of objections raised	71	154	71	84							**142**	**238**
Similarity with other (invented) name	57	120	58	66							**115**	**186**
Conveys misleading therapeutic connotations	1	5	0	1							**1**	**6**
Conveys misleading pharmaceutical connotations	1	1	2	2							**3**	**3**
Misleading with respect to composition	0	0	0	0							**0**	**0**
Similarity with INN	7	8	3	4							**10**	**12**
Inclusion of INN stem	0	0	1	2							**1**	**2**
Unacceptable qualifiers	0	0	1	1							**1**	**1**
Conveys a promotional message	0	6	1	3							**1**	**9**
Appears offensive or has an inappropriate connotation	0	2	2	0							**2**	**2**
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0							**0**	**0**
Similarity between name of prodrug and related active substance	0	0	0	0							**0**	**0**
Inclusion of common umbrella segment	0	0	0	0							**0**	**0**
Potential difficulties in pronunciation	0	5	1	2							**1**	**7**
Others	5	7	1	4							**6**	**11**

See *Guideline on the Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure (EMA/CHMP/287710/2014)* for detailed explanations of criteria used.